Background. Glomerular filtration rate (GFR) and comorbidity at dialysis initiation in relation to mortality in end-stage renal disease is still controversial. We studied factors potentially related to the mortality in incident haemodialysis (HD) patients. Methods. A national database included 23 551 incident HD patients from July 2001 to December 2004. Kaplan-Meier and Cox regression analyses were performed to assess the association between GFR estimated by the four-variable Modified Diet in Renal Disease equation and all-cause mortality. Analyses were performed from Day 91 after the start of dialysis. Patients were classified into five groups (quintiles) based on estimated glomerular filtration rate (eGFR) at the start of dialysis. Results. The median eGFR at dialysis initiation was low (4.7 mL/min/1.73 m 2 ), as was the mortality in the first year of dialysis [13.2/100 patient-year, 95% confidence interval (95% CI)=12.8-13.7]. There was an inverse association between lower eGFR and higher survival rate. The Cox regression model revealed an increase in mortality risk in Q5 (hazard ratio [HR]=2.44, 95% CI=2.11-2.81), Q4 (HR= 1.66, 95% CI=1.43-1.93), Q3 (HR=1.21, 95% CI=1.04-1.41) and Q2 (HR=1.18, 95% CI=1.01-1.37) compared with the reference group of Q1 after adjusting for year of application, primary diseases (chronic glomerulonephritis, diabetic nephropathy, hypertension, chronic tubulointerstitial nephritis and others), demographics (age, sex), presence of co-morbidity (diabetes mellitus, hypertension, congestive heart failure, ischaemic heart diseases, cerebrovascular diseases, malignancies, liver cirrhosis, tuberculosis, other diseases and free of reported of comorbidities) and haematocrit. Propensity score analysis also showed a higher eGFR to be associated with increased mortality risks. Adjustment for all covariates explained a high percentage of excess risk of mortality in the groups with low eGFR, but less risk in the groups with higher eGFR.
Introduction
Putative advantages of initiating dialysis at a higher glomerular filtration rate (GFR) or early dialysis in prolonging patient survival, preventing uraemic complications and improving quality of life [1] [2] [3] have led to various guidelines including a target estimated glomerular filtration rate (eGFR) as a criterion for dialysis initiation [4, 5] . For expected outcomes, almost all the published guidelines recommend initiating maintenance dialysis at an eGFR of around 8-10 mL/min/1.73 m 2 or even higher [4] [5] [6] . However, early initiation of dialysis incurs the risks of dialysisassociated complications, restriction of patient lifestyle and increasing medical expenditures. The level of GFR should not be the sole criterion for dialysis initiation. The status of nutrition and clinical condition are equivalently important criteria as eGFR.
However, a definite number, such as the level of GFR, could be conceptually taken as a more objective parameter for most clinicians; and thus, eGFR still plays a determinate role in the consideration of whether to initiate dialysis or persist with conservative treatment. Indeed, those patients initiating dialysis at high eGFR levels usually had a greater co-morbidity burden and were less able to tolerate uraemic symptoms [7, 8] , which might be the reason why most observational studies reported that early initiation of dialysis at a higher eGFR did not have a favourable effect on survival [9] [10] [11] [12] [13] [14] , even after extensive adjustment for severity of co-morbidities at the pre-end-stage renal disease (ESRD) stage [13, 14] .
In Taiwan, with the highest incidence and prevalence of ESRD [15, 16] , patients started dialysis with very low residual renal function (average eGFR, 5.0 mL/min/1.73 m 2 ; serum creatinine, 11.1 mg/dL; 2004) and in poor clinical conditions (haematocrit, 24.1%; serum albumin, 3.2 g/dL) [17] , but the mortality rate was low [16] . Similar findings were also reported in Japan, with an average eGFR of 5.47 mL/min/1.73 m 2 at dialysis initiation [18] . Given these results, the question of whether there is an ethnic difference in the association between renal function and the development of uraemic conditions has been raised, as well as whether the criteria for dialysis initiation based on the level of GFR should be reconsidered accordingly.
This study explores the characteristics and the clinical status of incident haemodialysis (HD) patients at dialysis initiation in Taiwan and examines whether the clinical condition and renal function at dialysis initiation is significantly related to the 1-year mortality rate of HD patients.
Materials and methods

Patient selection
In 2001, there were 22 405 568 residents in Taiwan, of which 51.1% were male. Based on the data from the Bureau of National Health Insurance in Taiwan, a total of 28 591 patients applied for long-term dialysis from July 2001 to December 2004. Since the National Health Insurance (NHI) registration data possibly included all patients with acute renal failure or multiple systems failure that met the criteria for application, we excluded those patients with age below 20 years, peritoneal dialysis as primary treatment, incomplete ID digits, eGFR > 15 mL/min/1.73 m 2 at initiation of dialysis or survival of <3 months (90 days). Finally, there were 23 551 cases included for analysis. There was no significant difference in age, sex, serum creatinine, eGFR and haematocrit between those with missing data and the whole study group, except for the distribution of primary diseases (data not shown). Information on death was based on the records from the Annual Death Report from the Department of Health, Taiwan.
Grouping and measurement
The incident HD patients were divided into quintiles based on eGFR level at dialysis initiation (Q1, <3.29; Q2, 3.29-4.27; Q3, 4.28-5.20; Q4, 5.21-6.51; Q5, >6.52 mL/min/1.73 m 2 ). The eGFR of each patient was calculated by the four-variable Modified Diet in Renal Disease (MDRD) equation [19, 20] (eGFR mL/min/1.73 m 2 =186 × Scr −1.154 × Age −0.203 × 0.742 (if female) × 1.212 (if black)). Selected variables for the study included year of application (2001-04), age, sex (male, female), primary diseases (chronic glomerulonephritis, diabetic nephropathy, hypertension, chronic tubulointerstitial nephritis and others), presence of co-morbidity at the time of dialysis initiation (diabetes mellitus, hypertension, congestive heart failure, ischaemic heart diseases, cerebrovascular diseases, malignancies, liver cirrhosis, tuberculosis, others and free of reported co-morbidities) and haematocrit (<24, 24-28, 28-32, ≥32%) at dialysis initiation. Missing data for the categorical variables were defined as unknown to reflect the contribution of other existing variables in the multivariate analyses.
Statistical analyses
Demographics and laboratory data were described as percentages, mean ± standard deviation or median within the 25th-75th percentile, and distributed differences between groups were analysed by chi-square test and one-way analysis of variance (ANOVA). Kaplan-Meier survival and Cox regression analysis were applied to explore the association between eGFR estimated by the four-variable MDRD equation and all-cause mortality. In the Cox regression model, time-dependent variables were used to assess proportional hazards assumption. Event occurrence was defined as an incident dialysis patient death within 1 year after dialysis initiation, and patients who survived over 365 days were considered as censored. Since the number of HD patients who received renal transplantation after dialysis initiation or shifted to peritoneal dialysis only accounted for a small portion of the study sample, they were not censored, but were included in survival analyses. Hazard ratios (HR) with 95% confidence interval (95% CI) were expressed.
In order to verify the robustness of the results and to reduce the selection bias, we estimated propensity score by multiple logistic regressions that defined treatment groups (high-or low-level eGFR) with median eGFR as dependent variable and included all the candidate variables (year of application, age, sex, primary diseases, diabetes mellitus, congestive heart failure, ischaemic heart diseases, cerebrovascular diseases, malignancies, liver cirrhosis, tuberculosis and haematocrit at dialysis initiation) which had an association with treatment groups in univariate analysis. Calibration effectiveness was evaluated by the Hosmer-Lemeshow test and receiver operating characteristic curve analysis. Predicted probability (propensity score) could be calculated through each patient's independent value by estimated logistic equation. Then, all patients were stratified into five subgroups based on the quintiles of the propensity score. The stratified method assumed that the baseline characteristics were similarly distributed within each stratum, and then the inescapable likely imbalance of choosing the high or low median of each eGFR group would be reduced. The quasi-randomized experiment is of advantage to reduce selection bias and is recommended for use on large datasets [21, 22] . The effectiveness of the propensity score was validated through the two-way ANOVA model. We created Cox regression models adjusted for propensity score and tested the consistency of the results in five quintiles of subgroups of propensity scores.
To ascertain which factors were the more important contributors to mortality risk, the excess risk explained (ERE) was calculated to study the contributions of factors to the mortality risks [23] . ERE was calculated by using the formula: % excess risk=1−(lnHR x //lnHR 1 ) where HR 1 is the HR of 1 year mortality for difference level of eGFR by univariate analysis and HR x is the HR calculated by multivariate analyses with adjustment (year of application, primary disease, demographics, presence of co-morbidity and haematocrit). Analyses were performed using SPSS version 12.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 4.0 was used for plotting the results (GraphPad Software Inc., San Diego CA, USA).
Results
Characteristics and clinical conditions of study population
Among a total of 23 551 incident ESRD patients enrolled, 47.7% of patients were male, with an average age of 61.5 ± 14.0 years. The median levels of serum creatinine at dialysis initiation were 10.1 mg/dL, corresponding to a median eGFR level of 4.7 mL/min/1.73 m 2 . Patients who began dialysis with an eGFR level in the fifth quintile were more often males (61.7%) and the majority were elderly (56.9%) and had diabetic nephropathy as primary disease (61.7%) than those in other groups ( Table 1) .
The states of presence of co-morbidity in groups of different quintiles of eGFR level are summarized in Table 2 . Nearly 57.9% of patients had co-morbidity data available for analysis, but the percentage of missing data slightly increased in the high eGFR group (57.7 vs 55.8% valid data in the eGFR groups Q1 and Q5), and only 9.0% of total analysis patients was free of reported co-morbidities. Diabetes (49.9%) and hypertension (66.5%) were the two most common co-morbidities. With the exception of hypertension, rates for co-morbidities increased with higher levels of eGFR at dialysis initiation, as shown in Table 2 .
Association of eGFR with mortality
The distribution of the eGFR and serum creatinine levels at dialysis initiation among all patients is shown in Figure 1 and compared to the data in the United States. The mortality rates in the first year post-dialysis were 5.9, 9.2, 10.9, 15.4 and 25.6 death/100 patient-year in groups with eGFR levels from the first to the fifth quintiles, respectively (Table 3) .
Based on the eGFR quintile group, the results of the Kaplan-Meier survival analysis are shown in Figure 2 . The mortality rates in the first year post-dialysis were 5.7, 8.9, 10.5, 14.5 and 23.0% in groups with eGFR levels from the first to the fifth quintiles, respectively. The survival curves among the five subgroups based on eGFR quintile at dialysis initiation also showed a lower survival rate in the group in the fifth quintile in contrast to a higher survival rate in the first quintile of eGFR (log-rank test, P < 0.001).
The adjusted HR and 95% CI for mortality were analysed by the Cox proportional hazard model as shown in Table 4 . After controlling for factors including age, sex, primary diseases, co-morbidities, year of application and haematocrit, the eGFR at dialysis initiation was a significant risk factor of mortality in the first year post-dialysis. There was a 144% increase in mortality risk in the group with an eGFR in the fifth quintile compared to the reference group in the first quintile (HR=2.44, 95% CI=2.11-2.81). A similar finding was noted in the group in the fourth quintile (HR = 1.66, 95% CI = 1.43-1.93), third quintile (HR=1.21, 95% CI=1.04-1.41) and second quintile (HR = 1.18, 95% CI= 1.01-1.37). Additionally, age, primary disease, congestive heart failure, cerebrovascular diseases, liver cirrhosis and malignancies were all significantly related to the increase of mortality risk. Hypertension and free of reported co-morbidities, by contrast, were associated with survival advantage. 
Propensity score model and excess risk explained for mortality
Multiple logistic regression analysis was used to create a propensity score and develop propensity strata to decrease the unequal distributions of factors between the lower and higher eGFR groups, which were demonstrated by F-statistics after stratification of the propensity score quintiles (data not shown). The influence of eGFR on mortality, analysed by Cox regression model adjusted by propensity score, showed an increase of mortality risk in patients in the group with the higher overall eGFR level (HR=1.83, 95% CI=1.69-1.99) and in each quintile subgroup stratified by propensity score (as shown in Figure 3 ). To explore which factors contributed to the mortality in various quintiles of eGFR, we used the ERE model (Table 5 ). In comparison with the results in the univariate analysis of Model 1, the HRs in all eGFR groups decreased by multivariable analysis after adjustment for all other variables in Model 2. The EREs of the eGFR groups in the second to fifth quintiles were 64.3, 69.8, 48.0 and 40.3%, respectively, in Model 2. The overall results indicate that, in groups with lower eGFR levels at dialysis initiation, the factors applied in the adjustment have a high degree of accuracy in explaining the risk of mortality. However, in groups with higher levels of eGFR, the adjusted factors explain <50% of the increased hazard, indicating that there were other unexplored factors which contributed to the mortality risk in the quintiles with a higher eGFR.
Discussion
The timing for initiation of dialysis is a controversial issue [11, 24] . Obrador et al. [7] reported a mean serum creatinine of 8.5 mg/dL and predicted GFR of 7.1 mL/min/1.73 m 2 at dialysis initiation from 90 897 US incident ESRD patients. In our study, the median serum creatinine and eGFR were 10.1 mg/dL and 4.7 mL/min/1.73 m 2 , respectively. Compared to the report of Obrador et al. [7] , our study patients started dialysis at a higher level of serum creatinine and a lower level of eGFR than the US patients ( Figure 1) . Kausz et al. [8] demonstrated that women, Hispanics and Asians and uninsured patients were more likely to start dialysis late, which might be partly due to financial barriers to access of care. Nevertheless, the employed patients, who were most likely to be insured, also started dialysis late. The explanation offered for this was that the employed patients represented a group of 'healthy workers' who were less motivated to receive dialysis therapy until the presence of severe uraemic symptoms [8] . However, under the NHI Programme, Taiwanese ESRD patients are able to access dialysis therapy without financial burden as soon as their clinical needs arise, either at ESRD or stages of chronic kidney disease (CKD). In a sense, accessibility to care should not be a cause of dialysis at a low eGFR in Taiwan. The pre-ESRD patients in Taiwan are more likely to wait for the presence of uraemic symptoms and other clinical signs rather than initiate dialysis according to GFR-based criteria. The reason of such delay in dialysis initiation possibly involves personal awareness and attitude towards dialysis treatment. In two recent studies on CKD epidemiology and awareness in Taiwan, the rate of awareness of CKD is only 3.5% overall in CKD Stages 1-5 [25] and 9.7% for Stages 3-5 [26] . Nearly 30% of CKD Stage 5 patients still have no sense of kidney disease [26] . This low awareness of CKD could hinder the acceptance of dialysis treatment at an optimal time point for initiation. Data are expressed as numbers and percentages (in parenthesis) for categorical variables. The eGFR is calculated by the four-variable MDRD equation. *P-value < 0.05, all the parameters show significant differences among groups by chi-square test.
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The presence of uraemic symptoms/signs and comorbidities varies in individuals with ESRD and does affect the decision concerning the timing of dialysis initiation. In Kausz's study [8] , patients with co-morbidities such as diabetes, cardiac disease, peripheral vascular disease and poor functional status were less likely to start dialysis at a low level of eGFR. Similarly, in a study of incident ESRD patients with co-morbidities such as diabetes, cardiovascular diseases and other systemic diseases, patients were more likely to start dialysis at a higher level of eGFR [9] . Our findings are consistent with this report and indicate that the patients who initiated dialysis at a higher eGFR level were in worse systemic conditions than the status of renal function itself, and thus, even at high levels of GFR, the sicker patients were unable to tolerate the disease burden without initiating dialysis therapy, which might be the reason why incident HD patients who initiate dialysis at a higher eGFR level did not show better outcomes, independent of co-morbid status and adverse demographics. The current finding indicates that presence of hypertension showed an independent protective effect on survival. One possible explanation for this result might be that we analysed hypertension as a binary variable (yes or no) instead of using pulse pressure as a continuous variable [27] . The [7] . patients who were being treated with anti-hypertensive medications and had become normotensive could be reported and categorized as hypertensive. The cardioprotective effect of anti-hypertensive therapy for hypertensive patients and the detrimental effect of hypotension in dialysis patients may explain the W-shaped mortality curve for dialysis patients with hypertension [28] . In addition to the survival analysis adjusted by the number of existing co-morbidities, Beddhu et al. [13] used a propensity score model to minimize the unequal distribution of co-morbidity and found a higher mortality risk associated with incident HD patients with higher eGFRs. The results of the propensity score model in this study provide additional support to our hypothesis that the patients with higher eGFR at dialysis initiation had a higher shortterm mortality rate. Furthermore, through the ERE model and the process of 'add-on', the significant effects of demographics, primary disease and co-morbidity on the lower eGFRs groups were demonstrated. On the other hand, demographic factors, primary disease and co-morbidity explained <50% of the risk for mortality in the higher eGFR groups, which means there were other unexplored factors contributing to mortality in the higher eGFR groups. As Kazmi et al. [14] reported, a greater risk for death was found in all study groups initiating dialysis at a higher GFR, and when sequentially adjusted for additional covariates associated with the effect, the results could not be fully explained by co-morbidity.
The association between levels of eGFR at dialysis initiation and mortality is still controversial. With the exception of the report by Tang et al. from Hong Kong [29] , the conclusions of our study, which found that early initiation of dialysis at a higher GFR level did not have better prognosis compared to late dialysis, are consistent with previous studies from various countries [9, 10, [12] [13] [14] 30, 31] . Data from the recent published annual report of the Japanese Society of Dialysis Therapy also showed findings similar to ours. In addition to a low average level of eGFR at dialysis initiation, higher eGFR independently had a high mortality risk after adjustment for age, sex and primary diseases [18] . Furthermore, in a recent report, Sawhney et al. compared the survival and dialysis initiation between British Columbia and Scotland and found that starting dialysis at lower levels of eGFR was associated with low risk of mortality [32] . The studies conducted by the The Netherlands Cooperative Study on the Adequacy of Dialysis Study (NECOSAD) study group [10, 33] also demonstrated that start of dialysis at a high level of eGFR was not associated with better health-related quality of life, and the authors questioned the benefit of the United States-National Kidney Foundation Dialysis Outcomes Quality Initiative (US-NKFDOQI) guidelines in daily practice. However, the problems of lead-time bias, insufficient case number and too early to make a conclusion were also raised in that study [11] . A recent published study using the European Renal Association-European Dialysis Transplantation Association (ERA-EDTA) Registry data for incident dialysis patients in 1999 and 2003 by Stel et al. [34] came to a similar conclusion that higher eGFR at the start of dialysis was associated with a higher mortality risk.
Rosansky et al. [35] noted a trend towards increasingly higher eGFR at the initiation of dialysis in the US compared to the past decade. In their review, available data indicate that mortality may be higher in those subjects with early initiation and co-morbidities are not considered a major driving force for early initiation patients. The importance of residual renal function and the financial impact on the health care system are stressed [35] . Taiwan already has the highest ESRD incidence and prevalence in the world [15] . If initiating dialysis at higher eGFR level, which has not been proved beneficial so far, is advocated as firmly as in the guidelines, a further increase in dialysis case numbers and financial burden are unavoidable. However, the best timing for initiation of dialysis should not be solely dependent on the level of GFR. Clinical judgment based on individual condition and co-morbidity should always be emphasized.
As in other retrospective observational studies, there may be problems in the present study related to leadtime bias, inequity in disease burden at different levels of GFR and personal factors related to decision making concerning the timing of dialysis initiation. Though the NECOSAD study [10, 33] and the Tang study [29] were prospectively designed and conducted, the case numbers were insufficient for adequate power estimation so that small-scale retrospective studies were not persuasive either [11] . Until the results of the Initiation of Dialysis Early and Late trial (IDEAL trial) [36] , a prospective randomized control study performed in Australia and New Zealand, the inconsistent results on the association of eGFR with mortality generated by observational studies will remain inconclusive.
Despite the advantage of national data with a large number of study cases, there are several potential limitations in the present study. First, this was a retrospective study of secondary data analysis. The limited items used as clinical parameters and incomplete information due to primary data errors at the time of dialysis application were neither avoided nor overlooked. Second, laboratory data of the incident HD patients were measured at different hospitals and by different laboratory equipment. The calibration or standardization of creatinine measurements was absent. The non-standardized methods of serum creatinine measurement and the subsequent calculated results of eGFR from serum creatinine may have led to misclassification of the eGFR groups. Third, since the four-variable MDRD equation was developed from non-Asian subjects, its validity in Asians has been questioned [37, 38] . Though there were eGFR equations modified from the four-variable MDRD equation for Chinese [37] and Japanese patients [38, 39] , the work on the development of a Taiwanese GFR equation is still ongoing. Thus, the validity of the four-variable MDRD formula in Taiwanese and in patients with such low GFR levels must be interpreted with caution. Fourth, patients who survived <90 days were excluded from this study because of the possibility of including pa- Model 1 is the univariate analysis based on eGFR with the group Q1 as reference group; Model 2 is the multivariate analysis-adjusted age, sex, year of application, primary diseases (chronic glomerulonephritis, diabetic nephropathy, hypertensive nephrosclerosis, chronic tubulointerstitial nephritis and others), presence of co-morbidity (diabetes mellitus, hypertension, congestive heart failure, ischaemic heart diseases, cerebrovascular diseases, malignancies tuberculosis, others and free of reported co-morbidities) and haematocrit. ERE (%): ERE=1−(lnHR x /lnHR 1 ) between different models at the same level of eGFR group [23] .
tients with acute renal failure or terminal illness with renal failure patients. Thus, the 1-year mortality always includes survival for the first 3 months. Finally, the adjustment for co-morbidities was based on the eGFR categories, but the severity of co-morbidities, active or inactive, past or present, was not available from the dataset. Nonetheless, this study still has its value in prompting reappraisal of the appropriateness of existing dialysis guidelines in predicting outcomes and providing evidence for the establishment of the cross-national criteria based on data from Taiwanese patients.
Conclusion
In conclusion, lower eGFR at dialysis initiation is associated with lower mortality in Taiwanese ESRD patients, even in those with very low median ranges of eGFR. Factors other than demographics, primary diseases and comorbidities at dialysis initiation contribute to mortality and account for the association between eGFR and mortality, especially in patients initiating dialysis at higher eGFR levels.
